Search results
Results from the WOW.Com Content Network
Testosterone replacement therapy (TRT), or testosterone therapy, is a form of hormone replacement therapy for men. This treatment uses synthetic testosterone to increase circulating testosterone ...
Along with triptorelin and goserelin, it has been used to delay puberty in transgender youth until they are old enough to begin hormone replacement therapy. [17] Researchers have recommended puberty blockers after age 12, when the person has developed to Tanner stages 2–3, and then cross-sex hormones treatment at age 16.
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
Gender-affirming hormone therapy (GAHT), also called hormone replacement therapy (HRT) or transgender hormone therapy, is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity.
During HRT, especially in the early stages of treatment, blood tests should be consistently done to assess hormone levels and liver function. Gianna Israel and colleagues have suggested that for pre- oophorectomy trans men, therapeutic testosterone levels should optimally fall within the normal male range, whereas estrogen levels should ...
DIY transgender hormone therapy is a phenomenon where transgender people obtain and self-administer transgender hormone therapy as part of their gender transition without the guidance of a licensed medical provider. This may be caused by various problems accessing healthcare which transgender people face.
Testosterone therapy for patients with late-onset hypogonadism, in addition to increasing risk of cardiovascular disease and prostate cancer, may exacerbate the risk factors associated with benign prostatic hyperplasia, a condition that involves the noncancerous enlargement of the prostate gland, which can lead to urinary symptoms.
In the EPC trial, in which bicalutamide monotherapy (150 mg/day) was evaluated for treatment of early prostate cancer in 8,113 men, the incidence of abnormal liver function tests at 3-year median follow-up was 3.4% for bicalutamide plus standard care (n=4,052) and 1.9% for standard care alone (n=4,061).